Ana Rita Ferreira

Dr. Ana Rita Ferreira

iBiMED - Institute of Biomedicine, University of Aveiro
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2016 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
AFAna Rita Ferreira
Ana Rita Ferreira
AMAna Cristina Magalhaes
Ana Cristina Magalhaes
FCFátima Camões
Fátima Camões
AGAna Gouveia
Ana Gouveia
MVMarta Vieira
Marta Vieira
DRDaniela Ribeiro
Daniela Ribeiro
Hepatitis C virus (HCV) is the cause of one of the most prevalent viral infections worldwide. Upon infection, the HCV genome activates the RIG‐I‐MAVS signalling pathway leading to the production of direct antiviral effectors which prevent important steps in viral propagation.MAVS localizes at peroxisomes and mitochondria and coordinate the activation of an effective antiviral response: peroxisomal MAVS is responsible for a rapid but short‐termed antiviral response, while the mitochondrial MAVS is associated with the activation of a stable response with delayed kinetics.The HCV NS3‐4A protease was shown to specifically cleave the mitochondrial MAVS, inhibiting the downstream response.In this study, we have analysed whether HCV NS3‐4A is also able to cleave the peroxisomal MAVS and whether this would have any effect on the cellular antiviral response. We show that NS3‐4A is indeed able to specifically cleave this protein and release it into the cytosol, a mechanism that seems to occur at a similar kinetic rate as the cleavage of the mitochondrial MAVS. Under these conditions, RIG‐I‐like receptor (RLR) signalling from peroxisomes is blocked and antiviral gene expression is inhibited. Our results also show that NS3‐4A is able to localize at peroxisomes in the absence of MAVS. However, mutation studies have shown that this localization pattern is preferred in the presence of a fully cleavable MAVS. These findings present evidence of a viral evasion strategy that disrupts RLR signalling on peroxisomes and provide an excellent example of how a single viral evasion strategy can block innate immune signalling from different organelles.

16 May 2016 in Scientific Reports
Verified
Journal Article
Open access
AMAna Cristina Magalhaes
Ana Cristina Magalhaes
AFAna Rita Ferreira
Ana Rita Ferreira
SGSílvia Gomes
Sílvia Gomes
MVMarta Vieira
Marta Vieira
AGAna Gouveia
Ana Gouveia
DRDaniela Ribeiro
Daniela Ribeiro
The human cytomegalovirus developed distinct evasion mechanisms from the cellular antiviral response involving vMIA, a virally-encoded protein that is not only able to prevent cellular apoptosis but also to inhibit signalling downstream from mitochondrial MAVS. vMIA has been shown to localize at mitochondria and to trigger their fragmentation, a phenomenon proven to be essential for the signalling inhibition. Here, we demonstrate that vMIA is also localized at peroxisomes, induces their fragmentation and inhibits the peroxisomal-dependent antiviral signalling pathway. Importantly, we demonstrate that peroxisomal fragmentation is not essential for vMIA to specifically inhibit signalling downstream the peroxisomal MAVS. We also show that vMIA interacts with the cytoplasmic chaperone Pex19, suggesting that the virus has developed a strategy to highjack the peroxisomal membrane proteins’ transport machinery. Furthermore, we show that vMIA is able to specifically interact with the peroxisomal MAVS. Our results demonstrate that peroxisomes constitute a platform for evasion of the cellular antiviral response and that the human cytomegalovirus has developed a mechanism by which it is able to specifically evade the peroxisomal MAVS-dependent antiviral signalling.

1 February 2022 in Trends in Cell Biology
Verified
Journal Article
Closed access
AFAna Rita Ferreira
Ana Rita Ferreira
MMMariana Marques
Mariana Marques
BRBruno Ramos
Bruno Ramos
JKJonathan C. Kagan
Jonathan C. Kagan
DRDaniela Ribeiro
Daniela Ribeiro

Verified
Journal Article
Open access
PDF file
AFAna Rita Ferreira
Ana Rita Ferreira
MMMariana Marques
Mariana Marques
DRDaniela Ribeiro
Daniela Ribeiro
Peroxisomes are ubiquitous organelles with well-defined functions in lipid and reactive oxygen species metabolism, having a significant impact on a large number of important diseases. Growing evidence points to them, in concert with mitochondria, as important players within the antiviral response. In this review we summarize and discuss the recent findings concerning the relevance of peroxisomes within innate immunity. We not only emphasize their importance as platforms for cellular antiviral signaling but also review the current information concerning their role in the control of bacterial infections. We furthermore review the recent data that pinpoints peroxisomes as regulators of inflammatory processes.

10 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AFAna Rita Ferreira
Ana Rita Ferreira
ARAna Catarina Ramalho
Ana Catarina Ramalho
MMMariana Marques
Mariana Marques
DRDaniela Ribeiro
Daniela Ribeiro
Human papillomaviruses (HPV) are the causative agents of the most common sexually transmitted infection worldwide. While infection is generally asymptomatic and can be cleared by the host immune system, when persistence occurs, HPV can become a risk factor for malignant transformation. Progression to cancer is actually an unintended consequence of the complex HPV life cycle. Different antiviral defence mechanisms recognize HPV early in infection, leading to the activation of the innate immune response. However, the virus has evolved several specific strategies to efficiently evade the antiviral immune signalling. Here, we review and discuss the interplay between HPV and the host cell innate immunity. We further highlight the evasion strategies developed by different HPV to escape this cellular response and focus on the correlation with HPV-induced persistence and tumorigenesis.

13 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAna Rita Ferreira
Ana Rita Ferreira
BRBruno Ramos
Bruno Ramos
ANAlexandre Nunes
Alexandre Nunes
DRDaniela Ribeiro
Daniela Ribeiro
Hepatitis C virus (HCV) infections constitute a major public health problem and are the main cause of chronic hepatitis and liver disease worldwide. The existing drugs, while effective, are expensive and associated with undesirable secondary effects. There is, hence, an urgent need to develop novel therapeutics, as well as an effective vaccine to prevent HCV infection. Understanding the interplay between HCV and the host cells will certainly contribute to better comprehend disease progression and may unravel possible new cellular targets for the development of novel antiviral therapeutics. Here, we review and discuss the interplay between HCV and the host cell innate immunity. We focus on the different cellular pathways that respond to, and counteract, HCV infection and highlight the evasion strategies developed by the virus to escape this intracellular response.